Johnson & Johnson Avoids Obesity Drugs, Redirects $3.05B to Cancer Ambitions
LLY•Johnson & Johnson CEO Joaquin Duato confirmed the company will not pursue GLP-1 obesity treatments, instead targeting oncology and neuroscience. J&J paid $3.05 billion in 2025 for Halda Therapeutics’ oral prostate cancer therapy and aims to become the top cancer company by 2030.
1. J&J Exits GLP-1 Obesity Market
Chief Executive Joaquin Duato stated J&J will not develop or acquire GLP-1 obesity drugs, ceding that space to competitors with established weight-loss franchises. This decision positions existing players like Eli Lilly to capture a larger share of the growing obesity-treatment market.
2. Oncology and Neuroscience Priorities
J&J plans to concentrate R&D and capital on cancer and neurodegenerative diseases, citing the potential for greater patient impact. The company’s $3.05 billion acquisition of Halda Therapeutics in 2025 secures an oral prostate cancer candidate, and J&J targets global #1 oncology status by 2030.
3. Competitive Implications for Lilly
With J&J out of the GLP-1 space, Eli Lilly faces reduced near-term competition in the obesity segment, potentially bolstering its weight-loss drug sales trajectory. Lilly may also see strategic opportunities to leverage AI-driven drug discovery in response to shifting industry priorities.
